86 related articles for article (PubMed ID: 11489788)
1. Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Münster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001.
Sausville EA
Clin Cancer Res; 2001 Aug; 7(8):2155-8. PubMed ID: 11489788
[No Abstract] [Full Text] [Related]
2. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.
Münster PN; Basso A; Solit D; Norton L; Rosen N
Clin Cancer Res; 2001 Aug; 7(8):2228-36. PubMed ID: 11489796
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.
Münster PN; Srethapakdi M; Moasser MM; Rosen N
Cancer Res; 2001 Apr; 61(7):2945-52. PubMed ID: 11306472
[TBL] [Abstract][Full Text] [Related]
4. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S
Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005
[TBL] [Abstract][Full Text] [Related]
5. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
7. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
[TBL] [Abstract][Full Text] [Related]
8. [Heat shock protein 90: novel target for cancer therapy].
Chen Y; Ding J
Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer.
Neckers L
Clin Cancer Res; 2002 May; 8(5):962-6. PubMed ID: 12006507
[No Abstract] [Full Text] [Related]
10. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway.
Wang X; Ju W; Renouard J; Aden J; Belinsky SA; Lin Y
Cancer Res; 2006 Jan; 66(2):1089-95. PubMed ID: 16424045
[TBL] [Abstract][Full Text] [Related]
11. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
[TBL] [Abstract][Full Text] [Related]
12. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
Guo F; Rocha K; Bali P; Pranpat M; Fiskus W; Boyapalle S; Kumaraswamy S; Balasis M; Greedy B; Armitage ES; Lawrence N; Bhalla K
Cancer Res; 2005 Nov; 65(22):10536-44. PubMed ID: 16288046
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
[TBL] [Abstract][Full Text] [Related]
14. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
Yin X; Zhang H; Burrows F; Zhang L; Shores CG
Clin Cancer Res; 2005 May; 11(10):3889-96. PubMed ID: 15897590
[TBL] [Abstract][Full Text] [Related]
15. In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation.
Ochel HJ; Gademann G
Anticancer Res; 2006; 26(3A):2085-91. PubMed ID: 16827149
[TBL] [Abstract][Full Text] [Related]
16. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma.
Schmitt E; Maingret L; Puig PE; Rerole AL; Ghiringhelli F; Hammann A; Solary E; Kroemer G; Garrido C
Cancer Res; 2006 Apr; 66(8):4191-7. PubMed ID: 16618741
[TBL] [Abstract][Full Text] [Related]
17. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.
Russell JS; Burgan W; Oswald KA; Camphausen K; Tofilon PJ
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3749-55. PubMed ID: 14506167
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
[TBL] [Abstract][Full Text] [Related]
19. Synergistic inhibition of the glucocorticoid receptor by radicicol and benzoquinone ansamycins.
Rosenhagen MC; Young JC; Wochnik GM; Herr AS; Schmidt U; Hartl FU; Holsboer F; Rein T
Biol Chem; 2001 Mar; 382(3):499-504. PubMed ID: 11347901
[TBL] [Abstract][Full Text] [Related]
20. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
